These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31101442)

  • 1. A pharmacist-run anabolic osteoporosis clinic: An abaloparatide descriptive report.
    McGreevy JL; Kane MP; Busch RS; Bakst G; ElDeiry S
    J Am Pharm Assoc (2003); 2019; 59(4):593-597. PubMed ID: 31101442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year changes in bone mineral density and T scores in patients treated at a pharmacist-run teriparatide clinic.
    Stroup JS; Rivers SM; Abu-Baker AM; Kane MP
    Pharmacotherapy; 2007 Jun; 27(6):779-88. PubMed ID: 17542760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture.
    Saag KG; Williams SA; Wang Y; Weiss RJ; Cauley JA
    Clin Ther; 2020 Jun; 42(6):1099-1107.e1. PubMed ID: 32513495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study.
    Cosman F; Cooper C; Wang Y; Mitlak B; Varughese S; Williams SA
    Osteoporos Int; 2022 Aug; 33(8):1703-1714. PubMed ID: 35524068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.
    Cosman F; Peterson LR; Towler DA; Mitlak B; Wang Y; Cummings SR
    J Clin Endocrinol Metab; 2020 Nov; 105(11):3384-95. PubMed ID: 32658264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
    Bilezikian JP; Hattersley G; Fitzpatrick LA; Harris AG; Shevroja E; Banks K; Leder BZ; Zanchetta JR; Hans D
    Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.
    Miller PD; Troy S; Weiss RJ; Annett M; Schense J; Williams SA; Mitlak B
    Clin Drug Investig; 2021 Mar; 41(3):277-285. PubMed ID: 33638863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abaloparatide for the treatment of postmenopausal osteoporosis.
    Pietrogrande L; Raimondo E
    Drugs Today (Barc); 2018 May; 54(5):293-303. PubMed ID: 29911694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abaloparatide: A new pharmacological option for osteoporosis.
    Sleeman A; Clements JN
    Am J Health Syst Pharm; 2019 Jan; 76(3):130-135. PubMed ID: 30689744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
    Chew CK; Clarke BL
    Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study.
    Gold DT; Beckett T; Deal C; James AL; Mohseni M; McMillan A; Bailey T; Pearman L; Caminis J; Wang Y; Williams SA; Kernaghan JM
    Osteoporos Int; 2024 Aug; 35(8):1407-1415. PubMed ID: 38653862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abaloparatide: First Global Approval.
    Shirley M
    Drugs; 2017 Aug; 77(12):1363-1368. PubMed ID: 28624872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a Nationwide Pharmacist-Led Phone Outreach Program to Improve Osteoporosis Management in Older Women with Recently Sustained Fractures.
    Tso LS; Loi D; Mosley DG; Yi D; Stockl KM; Lew HC; Solow BK
    J Manag Care Spec Pharm; 2015 Sep; 21(9):803-10. PubMed ID: 26308227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacist-run zoledronic acid clinic.
    Traina AN; Kane MP; Bakst G; Abelseth JM; Busch RS
    Am J Health Syst Pharm; 2011 Aug; 68(15):1399-403. PubMed ID: 21785027
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.
    Merlotti D; Falchetti A; Chiodini I; Gennari L
    Expert Opin Pharmacother; 2019 May; 20(7):805-811. PubMed ID: 30856013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of sequential treatment with abaloparatide vs. teriparatide for United States women at increased risk of fracture.
    Hiligsmann M; Williams SA; Fitzpatrick LA; Silverman SS; Weiss R; Reginster JY
    Semin Arthritis Rheum; 2019 Oct; 49(2):184-196. PubMed ID: 30737062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abaloparatide and the Spine: A Narrative Review.
    Thompson JC; Wanderman N; Anderson PA; Freedman BA
    Clin Interv Aging; 2020; 15():1023-1033. PubMed ID: 32636617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.